BeyondSpring(BYSI) on Combating Lung Cancer
$BSYI is currently trending and has its market price doubled(at the time of writing) during premarket hours by over 200% after announcing its topline data of DUBLIN-3 trial in plinabulin in combination with docetaxel (DP) to treat 2nd and 3rd line NSCLC (EGFR wild type) compared to docetaxel alone (D) (n=559).
The first NDA submission of plinabulin in CIN prevention is under FDA priority review with a PDUFA date of November 30, 2021.
The ticker is $BSYI you can comment for more details.

Comments
Post a Comment